Drugs in ATC Class P02

Up to Top Level ATC Classes

Up to P - Antiparasitic products, insecticides and repellents

Subclasses in ATC: P02 - ANTHELMINTICS

P02B - ANTITREMATODALS

P02C - ANTINEMATODAL AGENTS

P02D - ANTICESTODALS

Market Dynamics and Patent Landscape for ATC Class P02 (Anthelmintics)

Last updated: April 25, 2026

What is the market structure for anthelmintics (ATC P02)?

Product segmentation by use-case

The ATC P02 universe is split between human deworming and veterinary parasite control, with different prescribing paths, reimbursement models, and IP strategies.

• Human anthelmintics (major pull from mass drug administration and endemic-country procurement)
  • Demand is driven by disease burden and public health campaigns rather than incremental patient dosing.
  • Price is constrained by tenders, national formularies, and WHO-linked procurement.
• Veterinary anthelmintics (volume-driven by livestock economics)
  • Demand tracks animal populations, feed costs, and resistance management.
  • Brands that extend protection via stewardship programs, combination products, and next-generation moieties hold longer commercial runway.

Core commercial subsegments

Across both human and veterinary, the dominant competitive axis is by mechanism of action (MoA) and whether products are single-active or combination:

1. Benzimidazoles
   • Albendazole, mebendazole.
2. Macrocyclic lactones
   • Ivermectin, abamectin, moxidectin.
3. Imidazothiazoles / related
   • Levamisole.
4. Aminoacetonitrile derivatives (veterinary stronghold)
   • N-(2,4-dimethylphenyl)-5-(1,2,4-triazol-1-ylmethyl)-3-methyl-1,3-thiazol-2-amine is not the right generic bucket; the practical point is this class includes a subset of veterinary-only actives (market access depends heavily on local registrations).
5. Newer or narrower-spectrum agents
   • Human pipeline focus often centers on neglected tropical diseases and larval stage specificity; veterinary focus often targets strong resistance profiles.

How resistance changes the market

Anthelmintics face recurring anthelmintic resistance, which shifts the market in three measurable ways:

• Switching from older MoAs to newer ones during resistance events.
• Growth of combination strategies (two active classes with different targets).
• Regulatory and stewardship pressure that favors sponsors with clinical evidence on resistance mitigation.

This resistance-driven dynamic affects the patent landscape by pushing applicants toward:

• New chemical entities (new scaffold, new target or binding mode),
• New combinations (fixed-dose combinations with defined dosing regimens),
• New formulations (release, stability, or administration route) where composition and method-of-use claims can still support exclusivity even when active moieties go generic.

Pricing and access

• Human: procurement-based pricing compresses margins, and patent leverage tends to end quickly once key compounds go generic. IP value concentrates in improved formulations, pediatric indications, and line extensions with differentiated clinical endpoints.
• Veterinary: longer product lifecycles can occur through sustained registrations and combination product lineups. Yet resistance shortens the effective value period of single MoA actives, increasing competitive churn.

Which patent strategies dominate anthelmintics (ATC P02)?

1) Primary patent value: composition + polymorph + manufacturing

For anthelmintics, the patent family architecture is commonly built around:

• Chemical composition claims (active + defined substituent scope).
• Salt forms and polymorphs (where relevant).
• Crystallinity and process claims (to protect manufacturing economics).
• Formulation claims (controlled release, improved solubility, veterinary palatability, or pour-on delivery).

Because many core MoAs are mature, generic entrants often clear most of the scope unless the originator still has:

• active line extensions (next-gen scaffold),
• protected intermediates and processes, or
• protected formulation and use.

2) Combination products as the exclusivity engine

Fixed-dose combinations are a key differentiator:

• They can restart IP if each component is generic but the combination regimen and dosing interval are claimed.
• They can also generate new regulatory dossiers and local brand equity, which matters in tender-driven human markets.

3) Method-of-use and regimen claims

Sponsors increasingly pursue claims tied to:

• specific parasite species coverage,
• specific life-stage targets (adult versus larval),
• specific dosing schedules (interval and duration),
• pediatric, pregnancy safety, or treatment monitoring.

In human anthelmintics, these claims can be decisive if the active is not novel but the clinical value proposition is.

4) Second-generation reformulation

Reformulation is a frequent route to extend value:

• improved bioavailability,
• reduced pill burden (lower dosing frequency),
• new route of administration (e.g., oral dispersible forms, injectables, topical, or slow-release platforms).

These can sustain brand presence even after chemical composition expiry.

Who holds the dominant IP lanes: branded originators vs generics?

Brand originators

Anthelmintics historically concentrate around a small number of large originators and specialty animal health companies. Their recurring approach is to keep a multi-family pipeline alive across:

• new active compounds,
• new combinations,
• protected manufacturing and polymorph/formulation.

Generics and “lifecycle challengers”

Generics dominate pricing, especially for widely used single-compound actives (albendazole, mebendazole, ivermectin). Their attack vectors typically target:

• expiry of core composition claims,
• non-infringement of specific polymorph/formulation,
• invalidity under prior art,
• and design-around by salt/form or dosing.

Patent settlement behavior

Where there are protected line extensions (combination, formulation, pediatric regimens), settlement terms often preserve originator brand position via:

• “carve-outs” for specific formulations or dosage strengths,
• delayed generic launches,
• or licensing of specific skus.

How does the patent landscape translate into commercial timing?

Family-level exclusivity mapping

Anthelmintics tend to have:

• a long patent tail on manufacturing and formulation after the core composition is filed,
• plus incremental use and combination filings layered after early approvals.

The result is a staggered exclusivity pattern where market entry dates depend more on which family remains in force than on the molecule alone.

Typical “value compression” curve

• Post-approval year 0 to 7: chemical composition and initial formulations often dominate infringement risk.
• Years ~7 to 15: generics test around formulation, salt, and specific method-of-use claims.
• After active moiety expiry: remaining leverage is mostly in combination products and route/formulation claims.

What does the patent landscape look like by leading MoA class?

Benzimidazoles (albendazole, mebendazole)

• IP posture: largely mature. Value today concentrates on:
  • formulation improvements,
  • pediatric dosing regimens and safety data,
  • fixed-dose combinations for specific NTD strategies.
• Generic competition: high; many markets are saturated.

Macrocyclic lactones (ivermectin, moxidectin, abamectin)

• IP posture: mixed maturity by geography and by product line.
• Resistance-driven combination demand increases opportunities for next-gen regimens.

Imidazothiazoles and related (levamisole)

• IP posture: mature.
• Value: mostly formulation and local regulatory lifecycle management.

Newer veterinary-focused actives

• IP posture: more active filings often cluster here due to resistance and changing regulatory expectations in livestock systems.
• Value: tends to be protected longer via combination and delivery system patents.

Key market drivers that affect patent filings in ATC P02

1. Anthelmintic resistance
   • Increases incentives for new targets and for multi-target combinations.
2. NTD programs and tender procurement
   • Drives sponsors toward fast-to-regulatory strategies and lifecycle extensions that fit procurement schedules.
3. Veterinary animal health economics
   • Supports longer brand lifecycles but also forces rapid switching when resistance emerges.
4. Regulatory scrutiny
   • Pediatric and safety data requirements favor sponsors who can claim method-of-use and regimen value.

Actionable patent watch framework for ATC P02

For business planning, the highest-signal watch items are:

• Fixed-dose combinations where at least one component is still under protection, or where combination regimen claims survive.
• Polymorphs, salts, and crystallinity for key BCS compounds.
• Manufacturing process claims tied to intermediates or yield-critical steps.
• Method-of-use claims tied to parasite species, life stage, and treatment duration.
• Route-of-administration innovations where a delivery platform can support distinct claims.

Key Takeaways

• ATC P02 is a procurement- and resistance-driven market where combinations, formulations, and regimen claims often determine exclusivity beyond core MoAs.
• The patent landscape is typically staggered by family type: composition early, then manufacturing and formulation, then method-of-use and combinations.
• Resistance accelerates competitive churn and increases filing activity around combination strategies and next-generation delivery/regimen platforms.
• For investment or R&D prioritization, the most actionable patent signals are surviving combination, polymorph/formulation, and method-of-use families, not just the active moiety.

FAQs

1) Where do I typically find the strongest remaining exclusivity in anthelmintics after generic entry?

Fixed-dose combinations, protected formulation attributes (including polymorph/salt and delivery), and method-of-use/regimen claims that tie to specific parasite coverage and dosing schedules.

2) How does resistance influence the patent strategy of originators in ATC P02?

It pushes development toward multi-target regimens and next-generation actives, and it increases the value of claims linked to resistance management use patterns.

3) Why do tender-driven human procurement markets reduce the value of “simple” new filings?

Because procurement prices compress ROI, originator leverage must shift to differentiation that procurement can justify: pediatric regimens, combinations aligned with public health protocols, or formulation improvements that reduce adherence barriers.

4) What patent family elements most often block generic launches in mature anthelmintics?

Combination product claim sets, formulation-specific claims (including polymorph/crystallinity), and manufacturing/process claims that create non-infringement barriers.

5) What is the best practical way to monitor ATC P02 patent exposure?

Track patent families by claim category (composition, combination, formulation, method-of-use) and map them to products and dosage strengths by geography, rather than tracking only the active ingredient.

---

References

[1] WHO. “Model List of Essential Medicines” (accessed via WHO essential medicines resources).
[2] ATC/DDD Index, WHO Collaborating Centre for Drug Statistics Methodology. “P02 Anthelmintics” (ATC classification).
[3] EMA and/or FDA public labeling for key anthelmintic actives (public prescribing information, accessed via official label repositories).